Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 11
Positioning ADCs and CAR T in R/R Multiple Myeloma
Panelists discuss how sequencing CAR T-cell therapy, bispecifics, and antibody-drug conjugates (ADCs) will become increasingly complex, with treatment decisions depending on patient characteristics, accessibility, and toxicity profiles.
Sequencing CAR T, Bispecifics, and ADCs in Relapsed Myeloma
With increasing therapeutic options—including CAR T, bispecific antibodies, and antibody-drug conjugates—the sequencing of therapies in relapsed myeloma has become more complex. CAR T remains favored for fit patients due to its potential for treatment-free intervals.
ADC therapies like belantamab offer advantages in accessibility and ease of use, especially for patients who may not be candidates for cellular therapy. These agents are particularly suited for early relapse settings where logistical barriers exist.
Treatment decisions are increasingly personalized, based on prior therapies, patient preference, logistical feasibility, and the toxicity profiles of available options. This evolving landscape demands a more flexible and tailored approach to maximize outcomes.
Related Content:
